Tomaralimab
Based on 1 Customer Validation
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.42%
- CAS No.: 1449294-76-1
- Masse moléculaire:145.32 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG4 kappa
Human
|
IL-1β |
IL-6 |
IL-8 |
NLRP3 |
Tomaralimab (100-500 nM; 20 h) dose-dependently inhibits oligomeric tau-induced TLR2 activation in HEK-Blue hTLR2 cells, reducing SEAP levels [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:THP-1 cells
-
Concentration:100 nM, 500 nM
-
Incubation Time:24 h, 48 h
-
Result:Decreased the protein levels of TLR2, MyD88, NLRP3.
-
Cell Line:THP-1 cells
-
Concentration:100 nM, 500 nM
-
Incubation Time:24 h, 48 h
-
Result:Decreased the mRNA levels of proinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) induced by oligomeric tau.
Tomaralimab (25 mg/kg; i.v.; every other day; until day 19) attenuates DNCB‑induced atopic dermatitis (AD)‑like skin lesions in BALB/c mice[2].
Tomaralimab (10 mg/kg; i.p.; twice weekly) suppresses tumor growth and reduces PCNA-positive proliferating cells in NSG mice with human pancreatic ductal adenocarcinoma (PDAC) xenografts[3].
Tomaralimab (1.56-12.5 mg/kg; i.v.; 15 min before reperfusion) dose-dependently reduces infarct size by up to 45% and preserves cardiac function in porcine myocardial ischemia/reperfusion models[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (male, 18-23 g, ~7 weeks old) with DNCB-induced atopic dermatitis[2]
-
Dosage:25 mg/kg
-
Administration:Intravenous injection (i.v.); every other day; until day 19
-
Result:Reduced epidermal thickness, mast cell/macrophage infiltration, and pro-inflammatory cytokines (TSLP, IL-4, IL-13).
Increased filaggrin expression.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized Human TLR2 Protein can bind Tomaralimab. The EC50 for this effect is 649.63 ng/mL. -
Flow cytometric analysis of 1.5X106 THP-1 cells with Tomaralimab (HY-P99555, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1449294-76-1
-
Appearance Liquid
-
Masse moléculaire 145.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Tomaralimab]
-
Synonyms
OPN-305
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Kim Y, et al. TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice. Brain Behav Immun. 2024 Oct;121:291-302. [Content Brief]
[2]. Yeo H, et al. Therapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model. Biomed Rep. 2024 Dec 30;22(3):41. [Content Brief]
[3]. Lundy J, et al. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene. 2021 Oct;40(41):6007-6022. [Content Brief]
[5]. Arslan F, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tomaralimab Related Classifications
HY-P99555 Related Classifications
Powered by Bioz